Nuveen Asset Management LLC Buys 42,413 Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Nuveen Asset Management LLC boosted its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 13.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 361,515 shares of the company's stock after acquiring an additional 42,413 shares during the quarter. Nuveen Asset Management LLC owned 1.29% of Establishment Labs worth $16,655,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. R Squared Ltd purchased a new stake in Establishment Labs in the 4th quarter worth approximately $36,000. Handelsbanken Fonder AB lifted its holdings in Establishment Labs by 32.3% in the 4th quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company's stock worth $378,000 after buying an additional 2,000 shares during the period. Raymond James Financial Inc. purchased a new stake in Establishment Labs in the 4th quarter worth approximately $5,494,000. Black Swift Group LLC lifted its holdings in Establishment Labs by 98.6% in the 4th quarter. Black Swift Group LLC now owns 14,300 shares of the company's stock worth $659,000 after buying an additional 7,100 shares during the period. Finally, Swiss National Bank lifted its holdings in Establishment Labs by 2.7% in the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,774,000 after buying an additional 1,000 shares during the period. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ESTA has been the subject of several research analyst reports. Stephens reiterated an "overweight" rating and issued a $52.00 price objective on shares of Establishment Labs in a report on Thursday, March 6th. Wall Street Zen cut Establishment Labs from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. BTIG Research started coverage on Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 price objective for the company. Finally, Needham & Company LLC upgraded Establishment Labs from a "hold" rating to a "buy" rating and set a $48.00 target price for the company in a research note on Wednesday, May 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $55.33.

Establishment Labs Stock Down 0.5%

Shares of ESTA traded down $0.18 on Thursday, reaching $35.72. The stock had a trading volume of 29,821 shares, compared to its average volume of 471,046. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -13.80 and a beta of 0.73. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The company has a 50-day simple moving average of $34.14 and a 200-day simple moving average of $37.72. Establishment Labs Holdings Inc. has a 12-month low of $26.56 and a 12-month high of $58.00.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.13. The company had revenue of $41.38 million during the quarter, compared to analysts' expectations of $41.15 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The firm's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.58) EPS. Sell-side analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.